What the primary healthcare worker needs to know about the management of type 2 diabetes

References

• Diabetes. World Health Organization [homepage on the Internet]. c2012. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
   Google Scholar
• Kimani-Murage EW, Kahn K, Pettifor JM, et al. The prevalence of stunting, overweight and obesity, and metabolic disease risk in rural South African children. BMC Public Health. 2010;10:158.
   PubMed Web of Science ®Google Scholar
• Ludwig S, Clement M, Dunbar P, Johnson JA. Organization of diabetes care. Clinical practice guidelines for the prevention and management of diabetes. Can J Diab. 2008;32:S20–S24.
   Web of Science ®Google Scholar
• Distiller LA, Brown MA, Joffe BI, Kramer BD. Striving for the impossible dream: a community-based multi-practice collaborative model of diabetes management. Diabet Med. 2010;27(2):197–202.
   PubMed Web of Science ®Google Scholar
• Sample diabetes patient care flow sheet for adults. Clinical practice guidelines for the prevention and management of diabetes. Can J Diab. 2008;S195–197.
   Google Scholar
• Position statement: standards of medical care in diabetes–2012. Diabetes Care. 2012;35 Suppl 1:S11–S63.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
   PubMed Web of Science ®Google Scholar
• Harper W, Hanna A, Woo V, et al. Pharmacologic management of type 2 diabetes. Clinical practice guidelines for the prevention and management of diabetes. Canadian Journal of Diabetes. 2008;32:S53–S61.
   Web of Science ®Google Scholar
• Woodstock J, Sharfstein J, Hamburg M. Regulatory action on rosiglitazone by the US Food and Drug Administration. N Eng J Med. 2010;363(16):1489–1491.
   PubMed Web of Science ®Google Scholar
• Piccinni C, Motala D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diab Care. 2011;34(6):1369–1371.
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycaemic episodes and risk of dementia in older patients with type 2 diabetes. JAMA. 2009:301(15):1565–1572.
   PubMed Web of Science ®Google Scholar
• Pignone A, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diab Care. 2010;33(6):1395–1402.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Valentine WJ, Chen R, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant. 2008;23(4):1216–1223.
   PubMed Web of Science ®Google Scholar
• McFarlane P, Culleton B. Chronic kidney disease in diabetes: 2008 clinical practice guidelines. Canadian Medical Journal. 2008:S126–S133.
   Google Scholar
• Ballard DJ, Humphrey LL, Melon LJ, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Diabetes. 1998;37(4):405–412.
   Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456–1462.
   PubMed Web of Science ®Google Scholar
• Chaturvedi N. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? Ann Int Med. 2001;134(5):370–379.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685–693.
   PubMed Web of Science ®Google Scholar
• Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552–563.
   PubMed Web of Science ®Google Scholar
• Boyd SR, Altomere F. Retinopathy. Canadian Diabetes Association: 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diab. 2008;S134-S139.
   Google Scholar
• Seedat YK, Rayner BL. South Africn hypertension guideline 2011. S Afr Med J. 2012;102(1):57–88.
   Web of Science ®Google Scholar
• Culleton B, Drouin D, LaRochelle P, et al. Treatment of hypertension. Canadian Diabetes Association 2008: clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diab. 2008;32:S115–S118.
   Google Scholar
• Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817–824.
   PubMed Web of Science ®Google Scholar
• Bril V, Perkins B. Neuropathy. Canadian Diabetes Association 2008: clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diab. 2008; 32:S140–S142.
   Google Scholar
• Perkins BA, Olaleye D, Zinmen B, Bril V. Simple screening tests for neuropathy in the diabetes clinic. Diabetes Care. 2001;24(2):250–256.
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Bowering K, Ekoé J-M, Kalla TP. Foot care. Canadian Diabetes Association 2008: clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diab. 2008;32:S143–S146.
   Google Scholar